CN112399975B - 与Tie2结合的抗体及其用途 - Google Patents

与Tie2结合的抗体及其用途 Download PDF

Info

Publication number
CN112399975B
CN112399975B CN201980038199.8A CN201980038199A CN112399975B CN 112399975 B CN112399975 B CN 112399975B CN 201980038199 A CN201980038199 A CN 201980038199A CN 112399975 B CN112399975 B CN 112399975B
Authority
CN
China
Prior art keywords
ser
leu
gly
thr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980038199.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN112399975A (zh
Inventor
高圭永
裴点一
金载领
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Advanced Institute of Science and Technology KAIST
Institute for Basic Science
Original Assignee
Korea Advanced Institute of Science and Technology KAIST
Institute for Basic Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Advanced Institute of Science and Technology KAIST, Institute for Basic Science filed Critical Korea Advanced Institute of Science and Technology KAIST
Priority claimed from PCT/KR2019/006820 external-priority patent/WO2019235856A1/ko
Publication of CN112399975A publication Critical patent/CN112399975A/zh
Application granted granted Critical
Publication of CN112399975B publication Critical patent/CN112399975B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980038199.8A 2018-06-07 2019-06-05 与Tie2结合的抗体及其用途 Active CN112399975B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682042P 2018-06-07 2018-06-07
US62/682,042 2018-06-07
PCT/KR2019/006820 WO2019235856A1 (ko) 2018-06-07 2019-06-05 Tie2에 결합하는 항체 및 이의 용도

Publications (2)

Publication Number Publication Date
CN112399975A CN112399975A (zh) 2021-02-23
CN112399975B true CN112399975B (zh) 2024-05-17

Family

ID=69056780

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980038199.8A Active CN112399975B (zh) 2018-06-07 2019-06-05 与Tie2结合的抗体及其用途

Country Status (7)

Country Link
US (2) US12024562B2 (https=)
EP (2) EP3805265A4 (https=)
JP (2) JP7390317B2 (https=)
KR (1) KR102898574B1 (https=)
CN (1) CN112399975B (https=)
AU (2) AU2019283520A1 (https=)
CA (1) CA3101506A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7447144B2 (ja) * 2019-08-14 2024-03-11 ファームアブシン・インコーポレイテッド 抗ｔｉｅ２抗体及びその用途
AU2021242249A1 (en) * 2020-03-24 2022-08-18 Genentech, Inc. Tie2-binding agents and methods of use
KR102899889B1 (ko) * 2020-11-03 2025-12-18 한국생명공학연구원 신규 항-Tie2 항체 또는 이의 항원 결합 단편, 및 이의 용도
WO2022235090A1 (ko) * 2021-05-06 2022-11-10 기초과학연구원 Tie2 작용제 항체 및 이의 용도
KR20250005053A (ko) * 2022-01-13 2025-01-09 인제니아 테라퓨틱스 인크. Vegf 및 tie2-결합 융합 단백질 및 그의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
CN106994185A (zh) * 2016-01-22 2017-08-01 何玉龙 Tie2对视网膜及其他组织中静脉血管的保护作用及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM379494A0 (en) * 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
AU689232B2 (en) * 1994-02-10 1998-03-26 Ludwig Institute For Cancer Research An immunointeractive molecule which binds the (TIE)2/TEK receptor extracellular domain
JP2000041675A (ja) * 1998-07-31 2000-02-15 Nichirei Corp ヒトｔｅｋに対する抗体
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US20090137416A1 (en) * 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20040101920A1 (en) * 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JP2011102273A (ja) 2009-11-11 2011-05-26 Shiseido Co Ltd Ｔｉｅ２活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤
US10316105B2 (en) 2011-08-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Anti-TIE2 antibodies and uses thereof
MX359833B (es) * 2011-08-19 2018-10-12 Regeneron Pharma Anticuerpos anti-tie2 y usos de los mismos.
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
JP6346761B2 (ja) 2014-03-07 2018-06-20 丸善製薬株式会社 Ｔｉｅ２活性化剤、並びに医薬品組成物、及び経口組成物
JP6699551B2 (ja) * 2014-07-15 2020-05-27 アステラス製薬株式会社 新規抗ヒトＴｉｅ２抗体
JP2018043949A (ja) 2016-09-15 2018-03-22 サンスター株式会社 Ｔｉｅ２活性用組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
CN106994185A (zh) * 2016-01-22 2017-08-01 何玉龙 Tie2对视网膜及其他组织中静脉血管的保护作用及应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Dimerization of Tie2 mediated by its membrane-proximal FNIII domains;Jason O. Moore等;PNAS;第114卷(第17期);第4382-4387页 *

Also Published As

Publication number Publication date
EP3805265A1 (en) 2021-04-14
EP4591878A3 (en) 2025-10-22
JP7390317B2 (ja) 2023-12-01
KR20190139148A (ko) 2019-12-17
JP7700189B2 (ja) 2025-06-30
AU2026202090A1 (en) 2026-04-09
KR102898574B1 (ko) 2025-12-09
EP3805265A4 (en) 2022-07-06
US20250011438A1 (en) 2025-01-09
US12024562B2 (en) 2024-07-02
CA3101506A1 (en) 2019-12-12
JP2021526801A (ja) 2021-10-11
EP4591878A2 (en) 2025-07-30
JP2023175830A (ja) 2023-12-12
US20210179719A1 (en) 2021-06-17
CN112399975A (zh) 2021-02-23
AU2019283520A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
CN112399975B (zh) 与Tie2结合的抗体及其用途
JP7366068B2 (ja) 抗アンジオポエチン２抗体およびその使用
JP2022028654A (ja) Ｖｅｇｆ－ｇｒａｂタンパク質と薬物の結合体及びその用途
CN104540961A (zh) 双重受体拮抗性抗原结合蛋白及其用途
WO2019164219A1 (en) Anti-angiopoietin-2 antibodies and uses thereof
JP2025523049A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びその使用
WO2022017428A1 (zh) 抗ctla-4抗体及其用途
CN120981485A (zh) 抗ptk7抗体及其用途
WO2018035119A9 (en) Methods of treating cancer using bifunctional molecules that target growth factors
WO2021160138A1 (zh) 抗表皮生长因子受体的抗原结合蛋白及其应用
KR20220078568A (ko) Lrp5 단백질에 결합하는 항체 및 사용 방법
HK40130178A (en) Antibody binding to tie2 and use thereof
US12617848B2 (en) Methods of treating ocular pathologies using bifunctional molecules that target growth factors
US20220056120A1 (en) Methods of treating ocular pathologies using bifunctional molecules that target growth factors
KR20240056422A (ko) 인간 안지오포이에틴-2에 특이적으로 결합하는 제1 항원 결합 부위를 포함하는 이중특이적 항체 및 그 응용
KR20250130525A (ko) 신규한 항-Ang-2 항체 및 이의 용도
HK40115552A (zh) 抗ptk7抗体及其用途
WO2024022478A1 (zh) 结合大麻素受体cb1的抗体及其用途
HK40118737A (zh) 结合vegf和tie2的融合蛋白及其用途
CN118922443A (zh) 结合VEGF和Tie2的融合蛋白及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant